Atorvastatin/metformin controlled release - CJ Healthcare Corporation

Drug Profile

Atorvastatin/metformin controlled release - CJ Healthcare Corporation

Alternative Names: CJ-30056; Metformin/atorvastatin controlled release

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CJ HealthCare
  • Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Fatty acids; Heptanoic acids; Pyrroles; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hyperlipidaemia; Type 2 diabetes mellitus

Highest Development Phases

  • Phase III Hyperlipidaemia; Type 2 diabetes mellitus

Most Recent Events

  • 31 Jan 2016 Atorvastatin/metformin controlled release is available for licensing in World as of 31 Jan 2016. https://www.cjp.co.kr/
  • 23 Dec 2015 Phase-III clinical trials in Hyperlipidaemia in South Korea (PO) prior to December 2015 (CJ Healthcare pipeline, December 2015)
  • 23 Dec 2015 Phase-III clinical trials in Type-2 diabetes mellitus in South Korea (PO) prior to December 2015 (CJ Healthcare pipeline, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top